I thrilled to share our review and Beyond the Abstract on “The Changing Landscape of Immunotherapy for Advanced Renal Cancer” from https://t.co/RoiQGjukaU and https://t.co/0DvaVI9VE9
I really appreciate @BraunMDPhD's mentoring
@UroToday@YaleCancer@YaleMed@UrologicClinics
@KCRS26 is shaping up to be another fantastic meeting for the #kidneycancer community. Great science, great conversations, and great people! Hope to see many of you in Boston on July 23–24, or online if you can’t make the trip.
#KCRS26 will bring together leaders in kidney cancer research, clinical care, advocacy, industry, and the patient community.
In-person attendance is limited due to space constraints; however, virtual registration is free and open to all.
Register: https://t.co/KXWoIiUAAx
#KidneyCancer @kidneycan
Why do VEGFR-TKI + IO combinations produce impressive responses in ccRCC but often fail to achieve the long-term durability seen with dual checkpoint blockade? Check out our lab's latest in @Cancer_Cell led by the incredible Lyn Vuong!
https://t.co/ASvkCpDzQW
.@BraunMDPhD and colleagues tested a “live tumor fragment” lab assay/elive platform using biopsies to predict response to ICI. In a small validation (20 pts later treated with ICI) the Elephas score correctly flagged 82% of responders and 100% of non-responders, including 2 responders missed by standard biomarkers. Larger validation is ongoing. #ASCO26 @SmilowCancer@ASCO@OncoAlert
.@BraunMDPhD & Dr. Zachary Yochum @YaleHemOnc at #ASCO26: Spatial multi-omics mapping of #kidney tumors showed aggressive rhabdoid/sarcomatoid regions are rich in immune cells, with T cells that appear both activated and exhausted. These findings may help explain why some high-risk tumors still respond to checkpoint immunotherapy. @ASCO@SmilowCancer@OncoAlert
At #ASCO26, @kashimamdphd@BraunMDPhD share why some #kidneycancer tumors don’t respond to immunotherapy despite having plenty of T cells. Research found many T cells are “exhausted” and unable to fight cancer effectively, likely due to TGF-β signaling. Blocking TGF-β1 helped restore T cell activity, pointing to a potential new way to overcome resistance. @ASCO@SmilowCancer@OncoAlert
We are proud of our GU Clinical Research Director Dr. Brad McGregor @BradMcG04 who just received his @DanaFarber Clinical Innovation Award certificate!
Welcome to the 2026 #SITC#Sparkathon participants (Sparkies). We would like to thank them for participating in this unique program to advance their careers in immuno-oncology! #TCells#IO#SITCQuestfor100
Dr. Kato on MONSTAR-SCREEN-3.
Ultra-sensitive ctDNA MRD in resectable RCC:
- Feasible in 100% of patients (16/16)
- Baseline ctDNA detected in 100%; 50% at ultra-low levels
- Post-op MRD+ rates (small numbers): 13.3% (1 mo), 15.4% (3 mo), 10% (6 mo)
- In the only recurrence so far, MRD led imaging by around 4.4 months
Clinical outcomes are awaited to provide further insight into the role of ctDNA in RCC.
#GU26
#RCC
@OncoAlert@OncBrothers
🎯@DrChoueiri is rocking the stage again on adjuvant tx of #kidneycancer!
Phase 3 LITESPARK-022: In high-risk ccRCC post-nephrectomy, adjuvant pembrolizumab + belzutifan significantly improved DFS vs pembro alone (HR 0.72; 24-mo DFS 80.7% vs 73.7%).
OS immature. Manageable safety; ↑ grade ≥3 AEs (52.1% vs 30.2%).
Potential new SOC!
@ASCO #GU26 @DrChoueiri@DrYukselUrun@OncoAlert@DanaFarber_GU